LEGN - Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients | Benzinga
On Tuesday, Johnson & Johnson (NYSE:JNJ) announced results from a prespecified second interim analysis of Phase 3 CARTITUDE-4 study evaluating Carvykti (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone for relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy.
In simple words, the study compared Carvykti, a treatment for multiple myeloma, to other standard therapies. This research focused on patients whose multiple myeloma has returned or did not respond to initial treatments, after only one previous treatment.
The interim analysis showed a statistically significant and clinically meaningful improvement in overall survival for ...